These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24308434)

  • 1. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.
    Surget S; Lemieux-Blanchard E; Maïga S; Descamps G; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
    Leuk Lymphoma; 2014 Sep; 55(9):2165-73. PubMed ID: 24308434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
    Gillardin PS; Descamps G; Maiga S; Tessoulin B; Djamai H; Lucani B; Chiron D; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C; Moreau-Aubry A
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.
    Gaul L; Mandl-Weber S; Baumann P; Emmerich B; Schmidmaier R
    J Cancer Res Clin Oncol; 2008 Feb; 134(2):245-53. PubMed ID: 17653574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
    Tessoulin B; Descamps G; Moreau P; Maïga S; Lodé L; Godon C; Marionneau-Lambot S; Oullier T; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Blood; 2014 Sep; 124(10):1626-36. PubMed ID: 25006124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
    Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
    Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe.
    Cives M; Ciavarella S; Rizzo FM; De Matteo M; Dammacco F; Silvestris F
    Cell Signal; 2013 May; 25(5):1108-17. PubMed ID: 23380051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
    Durand R; Descamps G; Bellanger C; Dousset C; Maïga S; Alberge JB; Derrien J; Cruard J; Minvielle S; Lilli NL; Godon C; Le Bris Y; Tessoulin B; Amiot M; Gomez-Bougie P; Touzeau C; Moreau P; Chiron D; Moreau-Aubry A; Pellat-Deceunynck C
    Blood; 2024 Mar; 143(13):1242-1258. PubMed ID: 38096363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
    Tessoulin B; Moreau-Aubry A; Descamps G; Gomez-Bougie P; Maïga S; Gaignard A; Chiron D; Ménoret E; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
    J Hematol Oncol; 2018 Dec; 11(1):137. PubMed ID: 30545397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
    Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
    Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
    Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
    Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.
    Gomez-Bougie P; Halliez M; Maïga S; Godon C; Kervoëlen C; Pellat-Deceunynck C; Moreau P; Amiot M
    Cancer Biol Ther; 2015; 16(1):60-5. PubMed ID: 25517601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins.
    Lu B; Li J; Pan J; Huang B; Liu J; Zheng D
    Acta Biochim Biophys Sin (Shanghai); 2013 Aug; 45(8):683-91. PubMed ID: 23688587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
    Strumberg D; Harstrick A; Doll K; Hoffmann B; Seeber S
    Anticancer Drugs; 1996 Jun; 7(4):415-21. PubMed ID: 8826610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
    Hunsucker SA; Magarotto V; Kuhn DJ; Kornblau SM; Wang M; Weber DM; Thomas SK; Shah JJ; Voorhees PM; Xie H; Cornfeld M; Nemeth JA; Orlowski RZ
    Br J Haematol; 2011 Mar; 152(5):579-92. PubMed ID: 21241278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
    Xiong T; Wei H; Chen X; Xiao H
    Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.
    Rojas EA; Corchete LA; San-Segundo L; Martínez-Blanch JF; Codoñer FM; Paíno T; Puig N; García-Sanz R; Mateos MV; Ocio EM; Misiewicz-Krzeminska I; Gutiérrez NC
    Clin Cancer Res; 2017 Nov; 23(21):6602-6615. PubMed ID: 28790111
    [No Abstract]   [Full Text] [Related]  

  • 18. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
    Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
    Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
    Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
    PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.